Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Micossi, P.
Right arrow Articles by Foa, P. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Micossi, P.
Right arrow Articles by Foa, P. P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 27, Issue 12 1196-1204, Copyright © 1978 by American Diabetes Association

ARTICLES

Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects

P Micossi, AE Pontiroli, SH Baron, RC Tamayo, F Lengel, M Bevilacqua, U Raggi, G Norbiato and PP Foa

Normal subjects and patients with adult-onset diabetes received 10 gm. of aspirin in four days. On the fourth day, the fasting serum glucose and the glucose response to oral glucose were decreased in both groups. These changes were associated with increased levels of serum insulin and pancreatic glucagon, although the glucagon responses to oral glucose were unchanged. In the diabetic patients, aspirin therapy was followed by a decreased glucose response to I.V. glucose and by the appearance of an early insulin peak, which could not be demonstrated before treatment. Aspirin did not affect the I.V. glucose tolerance in normal subjects, although it did enhance the early insulin peak. A decrease in the fasting levels of free fatty acids was noted in both groups, whereas the fasting level of triglycerides decreased only in the diabetic patients. Cholesterolemia did not change in either group. A few preliminary observations indicate that, in normal subjects, ibuprofen and ketoprofen, two other presumed prostaglandin inhibitors, did not affect fasting glycemia, glucose tolerance, or the insulin response to glucose. No changes were noted after the administration of placebo.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
R. P. Riechelmann, I. F. Tannock, L. Wang, E. D. Saad, N. A. Taback, and M. K. Krzyzanowska
Potential Drug Interactions and Duplicate Prescriptions Among Cancer Patients
J Natl Cancer Inst, April 18, 2007; 99(8): 592 - 600.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
W. G. Christen, U. A. Ajani, D. A. Schaumberg, R. J. Glynn, J. E. Manson, and C. H. Hennekens
Aspirin Use and Risk of Cataract in Posttrial Follow-up of Physicians' Health Study I
Arch Ophthalmol, March 1, 2001; 119(3): 405 - 412.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1978 by the American Diabetes Association.